- Home
- WERN vs ELVN Comparison
WERN vs ELVN Comparison
Compare WERN & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WERN | ELVN |
|---|---|---|
| Founded | 1956 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WERN | ELVN |
|---|---|---|
| Price | $42.20 | $49.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $33.79 | ★ $43.40 |
| AVG Volume (30 Days) | 879.2K | ★ 1.9M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,974,396,000.00 | N/A |
| Revenue This Year | $22.24 | N/A |
| Revenue Next Year | $6.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.06 | $14.79 |
| 52 Week High | $45.27 | $49.94 |
Technical Indicators
Market Signals| Indicator | WERN | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 66.84 |
| Support Level | $39.68 | $17.90 |
| Resistance Level | $45.27 | N/A |
| Average True Range (ATR) | 1.52 | 3.47 |
| MACD | -0.47 | 1.14 |
| Stochastic Oscillator | 44.72 | 92.69 |
Price Performance
Historical ComparisonAbout WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.